Ionis pioneers RNA-based medicines.
Ionis Pharmaceuticals, Inc. (IONS) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 07:18 ET. Consensus EPS estimate is $-1.22.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-29 | FY2026 Q2 | $-1.08 | $-0.69 | +36.1% | $267.95M |
| 2026-04-29 | FY2026 Q1 | $-0.85 | $-0.30 | +64.7% | $246.09M |
| 2026-02-26 | FY2025 Q4 | $-1.24 | $-1.41 | -14.0% | $203.00M |
| 2025-10-29 | FY2025 Q3 | $-1.15 | $-0.61 | +47.0% | $156.72M |
| 2025-07-30 | FY2025 Q2 | $0.27 | $0.78 | +188.9% | — |
| 2025-04-30 | FY2025 Q1 | $-1.11 | $-0.93 | +16.2% | $131.61M |
| 2025-02-19 | FY2024 Q4 | $-1.09 | $-0.66 | +39.4% | $226.58M |
| 2024-11-06 | FY2024 Q3 | $-1.16 | $-0.95 | +18.1% | $133.81M |
IONS has beaten consensus EPS in 7 of its last 8 reported quarters.
Highlights from IONS's Jul 29 report: EPS of -$0.69 — a big beat vs the -$1.08 estimate (+36%); revenue of $268M — a big beat vs the $189M consensus (+42%). Focus now shifts to launch execution and pipeline.
See IONS on the live calendar →